Tiziana Life Sciences Ltd(TLSA)Earnings, Financials & Key Ratios
TLSA•NASDAQ
Price updated Jun 19, 2026
AboutTiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.Show more
- Revenue$0
- EBITDA-$16M+12.4%
- Net Income-$12M+32.9%
- EPS (Diluted)-0.22+35.3%
- ROE-250.49%-77.7%
TLSA Key Insights
Tiziana Life Sciences Ltd (TLSA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 19 (bottom 19%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 15.7x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TLSA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TLSA Price & Volume
Tiziana Life Sciences Ltd (TLSA) stock price & volume — 10-year historical chart
Loading chart...
TLSA Growth Metrics
Tiziana Life Sciences Ltd (TLSA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-56.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-70.78%
Return on Capital
10 Years-431.28%
5 Years-133.31%
3 Years-172.91%
Last Year-329.69%
TLSA Recent Earnings
Tiziana Life Sciences Ltd (TLSA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 0/12 qtrs (0%)
Q2 2026Latest
May 1, 2026Metric
Actual
Est
EPS
$0.22-143.0%
$0.09
Rev
—
—
Q3 2025
Jul 8, 2025Metric
Actual
Est
EPS
$0.10-35.4%
$0.07
Rev
—
—
Q3 2025
Jun 23, 2025Metric
Actual
Est
EPS
$0.13
—
Rev
—
—
Q2 2025
May 20, 2025Metric
Actual
Est
EPS
$0.06
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 1, 2026 | $0.22vs $0.09-143.0% | — |
| Q3 2025 | Jul 8, 2025 | $0.10vs $0.07-35.4% | — |
| Q3 2025 | Jun 23, 2025 | $0.13 | — |
| Q2 2025 | May 20, 2025 | $0.06 | — |
Based on last 12 quarters of dataView full earnings history →
TLSA Peer Comparison
Tiziana Life Sciences Ltd (TLSA) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ARCT | 214.03M | 7.53 | -3.14 | -51.43% | -173.47% | -36.55% | 0.12 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 AGIO | 2.03B | 34.16 | -4.80 | 48.03% | -6.4% | -34.11% | 0.05 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 |
Compare TLSA vs Peers
Tiziana Life Sciences Ltd (TLSA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TLSA Income Statement
Tiziana Life Sciences Ltd (TLSA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - | - | - |
Operating Expenses | 7.29M | 8.25M | 7.82M | 7.77M | 28.03M | 27.37M | 14.59M | 17.98M | 15.79M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 0 | 0 | 0 | 0 | 13.21M | 855K | 0 | 0 | 0 |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
Research & Development | 2.96M | 4.67M | 4.34M | 2.91M | 5.99M | 13.21M | 12.96M | 8.11M | 5.23M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 4.33M | 3.57M | 3.48M | 4.86M | 8.82M | 13.31M | 1.63M | 9.87M | 10.56M |
Operating Income | -7.29M▲ 0% | -8.25M▼ 13.1% | -7.82M▲ 5.1% | -7.77M▲ 0.7% | -28.03M▼ 260.6% | -27.37M▲ 2.3% | -14.59M▲ 46.7% | -17.98M▼ 23.3% | -15.79M▲ 12.2% |
Operating Margin % | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | 15.39% | -13.14% | 5.12% | 0.65% | -260.56% | 2.33% | 46.72% | -23.3% | 12.18% |
EBITDA | -7.28M | -8.23M | -7.81M | -7.58M | -27.94M | -27.23M | -14.54M | -17.89M | -15.67M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | 15.49% | -13.12% | 5.14% | 3.03% | -268.8% | 2.52% | 46.63% | -23.07% | 12.4% |
D&A (Non-Cash Add-back) | 8K | 11K | 12.61K | 198K | 89.76K | 141K | 51K | 96K | 124K |
EBIT | -7.29M | -8.25M | -7.82M | -7.77M | -27.98M | -26.48M | -15.39M | -17.23M | -16.74M |
Net Interest Income | 0 | 0 | 0 | -72K | -312K | -176K | -7K | 1.14M | 808K |
Interest Income | 0 | 0 | 0 | 1K | 8K | 0 | 0 | 1.15M | 814K |
Interest Expense | 9K | 9K | 9.46K | 73K | 320K | 176K | 7K | 10K | 6K |
Other Income/Expense | -9K | -9K | -8.67K | -73K | -312K | 717K | -811K | 742K | -952K |
Pretax Income | -7.3M▲ 0% | -8.26M▼ 13.1% | -7.83M▲ 5.1% | -7.85M▼ 0.2% | -28.34M▼ 261.2% | -26.66M▲ 5.9% | -15.4M▲ 42.2% | -17.24M▼ 12.0% | -16.75M▲ 2.9% |
Pretax Margin % | - | - | - | - | - | - | - | - | - |
Income Tax | -89K | -1.49M | -1.53M | -540K | -2.21M | -3.24M | 0 | 449K | -4.88M |
Effective Tax Rate % | 1.22% | 17.99% | 19.58% | 6.88% | 7.79% | 12.15% | 0% | -2.6% | 29.16% |
Net Income | -7.21M▲ 0% | -6.77M▲ 6.1% | -6.3M▲ 7.0% | -7.31M▼ 16.0% | -26.13M▼ 257.7% | -23.42M▲ 10.4% | -15.4M▲ 34.2% | -17.69M▼ 14.9% | -11.86M▲ 32.9% |
Net Margin % | - | - | - | - | - | - | - | - | - |
Net Income Growth % | 16.5% | 6.08% | 6.96% | -15.98% | -257.66% | 10.39% | 34.25% | -14.9% | 32.94% |
Net Income (Continuing) | -7.21M | -6.77M | -6.3M | -7.31M | -26.13M | -23.42M | -15.4M | -17.69M | -11.86M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.14▲ 0% | -0.12▲ 14.3% | -0.09▲ 23.0% | -0.11▼ 19.0% | -0.54▼ 390.9% | -0.48▲ 11.1% | -0.30▲ 37.5% | -0.34▼ 13.3% | -0.22▲ 35.3% |
EPS Growth % | 22.22% | 14.29% | 23% | -19.05% | -390.91% | 11.11% | 37.5% | -13.33% | 35.29% |
EPS (Basic) | -0.14 | -0.12 | -0.09 | -0.11 | -0.54 | -0.48 | -0.30 | -0.34 | -0.22 |
Diluted Shares Outstanding | 53.2M | 58.49M | 68.24M | 68.24M | 48.65M | 48.97M | 50.76M | 50.76M | 53.34M |
Basic Shares Outstanding | 53.2M | 58.49M | 68.24M | 68.24M | 48.65M | 48.97M | 50.76M | 50.76M | 53.34M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
TLSA Balance Sheet
Tiziana Life Sciences Ltd (TLSA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 5.02M | 1.81M | 5.45M | 1.14M | 70.18M | 48.68M | 24.28M | 7.34M | 7.51M |
Cash & Short-Term Investments | 4.7M | 48K | 4.18M | 153K | 65.82M | 42.19M | 18.12M | 1.18M | 3.72M |
Cash Only | 4.7M | 48K | 4.18M | 153K | 65.82M | 42.19M | 18.12M | 1.18M | 3.72M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 3.78M | 5.27M | 5.86M | 6.05M | 3.69M |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | -2.28K | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 320K | 1.76M | 1.27M | 991K | 193K | 0 | 0 | 0 | 0 |
Total Non-Current Assets | 28K | 18K | 5.52K | 664K | 480K | 147K | 2.19M | 4.85M | 3.78M |
Property, Plant & Equipment | 28K | 18K | 5.52K | 334K | 359.51K | 17K | 389K | 293K | 187K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | -35.59K | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 132.59K | 130K | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1.81M | 4.55M | 3.59M |
Other Non-Current Assets | 0 | 0 | 0 | 330K | 23.49K | 0 | 0 | 0 | 0 |
Total Assets | 5.05M▲ 0% | 1.83M▼ 63.7% | 5.45M▲ 197.8% | 1.81M▼ 66.8% | 70.66M▲ 3808.0% | 48.83M▼ 30.9% | 26.48M▼ 45.8% | 12.18M▼ 54.0% | 11.28M▼ 7.4% |
Asset Turnover | - | - | - | - | - | - | - | - | - |
Asset Growth % | -45.39% | -63.75% | 197.84% | -66.85% | 3807.96% | -30.9% | -45.77% | -53.98% | -7.39% |
Total Current Liabilities | 1.74M | 3.51M | 5.04M | 5.58M | 7.98M | 7.55M | 6.66M | 6.54M | 7.35M |
Accounts Payable | 0 | 0 | 0 | 0 | 3.37M | 4.41M | 4.96M | 4.14M | 5.58M |
Days Payables Outstanding | - | - | - | - | - | - | - | - | - |
Short-Term Debt | 225K | 234K | 244.3K | 212K | 2.31M | 1.35M | 122K | 138K | 106K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 299K | 505K | 1.93M | 5.37M | 590.59K | -1.34M | -113K | -124K | -94K |
Current Ratio | 2.89x | 0.52x | 1.08x | 0.21x | 8.79x | 6.45x | 3.64x | 1.12x | 1.02x |
Quick Ratio | 2.89x | 0.52x | 1.08x | 0.21x | 8.79x | 6.45x | 3.64x | 1.12x | 1.02x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 1.44M | 3.01M | 3.11M | 411K | 290K | 0 | 243K | 109K | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 289.79K | 0 | 243K | 109K | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.44M | 3.01M | 3.11M | 411K | 207 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.74M | 3.51M | 5.04M | 5.99M | 8.27M | 7.55M | 6.91M | 6.65M | 7.35M |
Total Debt | 225K | 234K | 244.3K | 623K | 555K | 1.35M | 365K | 247K | 106K |
Net Debt | -4.48M | 186K | -3.94M | 470K | -65.27M | -42.19M | -17.76M | -936K | -3.62M |
Debt / Equity | 0.07x | - | 0.60x | - | 0.01x | 0.03x | 0.02x | 0.04x | 0.03x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Interest Coverage | -809.78x | -916.22x | -827.33x | -106.48x | -87.58x | -155.53x | -2083.71x | -1798.40x | -2632.33x |
Total Equity | 3.31M▲ 0% | -1.68M▼ 150.8% | 409.01K▲ 124.3% | -4.18M▼ 1122.0% | 62.39M▲ 1592.5% | 41.28M▼ 33.8% | 19.57M▼ 52.6% | 5.54M▼ 71.7% | 3.94M▼ 28.9% |
Equity Growth % | -61.03% | -150.78% | 124.3% | -1121.97% | 1592.49% | -33.83% | -52.59% | -71.71% | -28.9% |
Book Value per Share | 0.06 | -0.03 | 0.01 | -0.06 | 1.28 | 0.84 | 0.39 | 0.11 | 0.07 |
Total Shareholders' Equity | 3.31M | -1.68M | 409.01K | -4.18M | 45.71M | 41.28M | 19.57M | 5.54M | 3.94M |
Common Stock | 2.83M | 3.75M | 6.77M | 4.1M | 97K | 102K | 102K | 103K | 111K |
Retained Earnings | 11.04M | -29.75M | -39.9M | -43.15M | -84.65M | -108.06M | -116.26M | -133.68M | -144.83M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -1.32M | -1.57M | 0 |
Accumulated OCI | -8K | -19K | -30.73K | -35K | -52K | 119.15M | 115.57M | 117.06M | 116.99M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TLSA Cash Flow Statement
Tiziana Life Sciences Ltd (TLSA) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -5.62M | -5.68M | -3.63M | -5.29M | -8.76M | -16.13M | -15.99M | -12.42M | -1.22M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | 1.43% | -1.16% | 36.1% | -45.78% | -65.48% | -84.22% | 0.88% | 22.31% | 90.18% |
Net Income | -7.92M | -6.57M | -6.26M | -7.26M | -19.17M | -17.36M | -12.55M | -14M | -9.48M |
Depreciation & Amortization | 8.79K | 10.68K | 12.62K | 194.77K | 65.93K | 104.52K | 41.57K | 75.97K | 99.09K |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.35M | -895.98K | 1.08M | 1.55M | 10.56M | 1.7M | -2.53M | 2.75M | 8.6M |
Working Capital Changes | 951.66K | 1.78M | 1.53M | 223.59K | -215.69K | -573.01K | -948.89K | -1.25M | -441.1K |
Change in Receivables | 0 | 38.83K | -142K | -99.37K | -342.85K | 317.27K | -127.17K | -1.14M | -1.11M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Investing | -276.93K | -970 | 0 | -2.98K | -93.25K | 96.36K | -3.26M | -991.57K | -56.73K |
Capital Expenditures | -38.46K | -970 | 0 | -2.98K | -93.25K | -16.31K | 0 | 0 | -15.18K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 112.67K | -1.08M | -200.21K | 10.45K |
Cash from Financing | 1.28M | 1.16M | 7.96M | 1.31M | 54.12M | -17.05K | -44.84K | 31.65K | 3.6M |
Debt Issued (Net) | 779.13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -141K |
Equity Issued (Net) | 497.81K | 1000K | 1000K | 1000K | 1000K | 95.63K | 0 | 125.83K | 1000K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | -156.02K | -203.45K | -112.67K | -44.84K | -94.17K | 28.33K |
Net Change in Cash | -5.95M▲ 0% | -4.33M▲ 27.3% | 4.13M▲ 195.4% | -3.97M▼ 196.2% | 48.26M▲ 1314.4% | -17.59M▼ 136.4% | -19.62M▼ 11.5% | -13.4M▲ 31.7% | 2.03M▲ 115.1% |
Free Cash Flow | -5.65M▲ 0% | -5.68M▼ 0.5% | -3.63M▲ 36.1% | -5.29M▼ 45.9% | -8.76M▼ 65.4% | -16.15M▼ 84.4% | -15.99M▲ 1.0% | -12.42M▲ 22.3% | -1.23M▲ 90.1% |
FCF Margin % | - | - | - | - | - | - | - | - | - |
FCF Growth % | 0.75% | -0.49% | 36.11% | -45.86% | -65.43% | -84.36% | 0.98% | 22.31% | 90.06% |
FCF per Share | -0.11 | -0.10 | -0.05 | -0.08 | -0.18 | -0.33 | -0.31 | -0.24 | -0.02 |
FCF Conversion (FCF/Net Income) | 0.78x | 0.84x | 0.58x | 0.72x | 0.34x | 0.69x | 1.04x | 0.70x | 0.10x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TLSA Key Ratios
Tiziana Life Sciences Ltd (TLSA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -167.92% | -121.98% | -830.17% | -1540.08% | - | -89.79% | -45.18% | -50.61% | -140.92% | -250.49% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | -4572.49% | -966.81% | -420.58% | -481.72% |
Debt / Equity | 0.03x | 0.07x | - | 0.60x | - | 0.01x | 0.03x | 0.02x | 0.04x | 0.03x |
Interest Coverage | -478.56x | -809.78x | -916.22x | -827.33x | -106.48x | -87.58x | -155.53x | -2083.71x | -1798.40x | -2632.33x |
FCF Conversion | 0.66x | 0.78x | 0.84x | 0.58x | 0.72x | 0.34x | 0.69x | 1.04x | 0.70x | 0.10x |
Related:TLSA Dividend History·TLSA Revenue History·TLSA Price History·TLSA P/E History·TLSA Financial Ratios·TLSA Institutional Holders
TLSA Frequently Asked Questions
Tiziana Life Sciences Ltd (TLSA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tiziana Life Sciences Ltd (TLSA) grew revenue by 0.0% over the past year. Growth has been modest.
Tiziana Life Sciences Ltd (TLSA) reported a net loss of $34.2M for fiscal year 2024.
Dividend & Returns
Tiziana Life Sciences Ltd (TLSA) has a return on equity (ROE) of -250.5%. Negative ROE indicates the company is unprofitable.
Tiziana Life Sciences Ltd (TLSA) had negative free cash flow of $13.6M in fiscal year 2024, likely due to heavy capital investments.